Hims & Hers Faces Investor Skepticism Over New Pricing Model

The launch of the highly anticipated Wegovy pill on the Hims & Hers platform has been met with a tepid market response. Despite securing access to Novo Nordisk’s weight-loss medications, shares of the telehealth company retreated following the announcement, as investors scrutinized a pricing strategy that appears to undermine its traditional market position.

Competitive Edge Blunted by Premium Pricing

A primary concern for analysts is the company’s new subscription plan for weight management. After an introductory month priced at $39, customers will pay a recurring monthly fee of $149, which does not include the separate cost of the medication itself. According to Bank of America analyst Allen Lutz, this price point exceeds initial market expectations and is higher than the $145 offering from direct competitor Ro. This shift effectively erodes a key pillar of the company’s brand identity: its role as a low-cost provider in the fiercely competitive market for weight-loss treatments.

This strategic pivot from a discount to a mid-tier provider carries significant financial implications. Bank of America projects that the GLP-1-related business segment for Hims & Hers could contract by 31% by the end of this year. The stock’s performance mirrors these concerns. While shares initially rallied to around $27 in early March on news of the Novo Nordisk partnership, they have since pulled back to the $20 range.

Should investors sell immediately? Or is it worth buying Hims & Hers?

Legal Scrutiny and Persistent Short Interest

Operational challenges are compounded by a difficult legal backdrop. Since March 20, the law firm Kahn Swick & Foti has been investigating potential breaches of fiduciary duty by the company’s management. Furthermore, a substantial short interest continues to overhang the stock. Currently, approximately 83.3 million shares are sold short, representing about 40% of the freely tradable float. Although pressure from short sellers has eased recently, the overall technical environment remains tense.

Despite these headwinds and ongoing insider selling activity, the company reported robust financials for 2025, with revenue reaching $2.35 billion. For the current fiscal year 2026, management has set ambitious targets, forecasting revenue of up to $2.9 billion and an EBITDA between $300 million and $375 million. Achieving these goals is now contingent upon the successful execution of the new premium pricing strategy and the ability to maintain high retention rates among new Wegovy subscribers in the coming quarters.